Peihong Wu

1.0k citations
7 papers · 635 indexed · 1 hit paper · h-index 5
Topics
Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers)Metabolism, Diabetes, and Cancer (2 papers)Diabetes Management and Research (2 papers)
Partner nations
China

In The Last Decade

Peihong Wu

6 papers receiving 624 citations

Hit Papers

Treatment of Type 2 Diabetes and Dyslipidemia with the Na...20082026201420202008100200300400

Peers

Peihong Wu
Comparison fields: 5 of 74
  • Pharmacology 346
  • Endocrinology, Diabetes and Metabolism 245
  • Molecular Biology 234
  • Pharmacology 121
  • Plant Science 92
Replace Jinfeng Tang with:
Jinfeng Tang China
Rong Xue China
Jiarong Lan China
Suling Huang China
Lili Yang China
Chengjuan Gu China
Krit Jaikumkao Thailand
Hyunghee Lee South Korea
Shangquan Liu China
Zhaojie Meng United States
Peihong Wu relative to Jinfeng Tang China Jinfeng Tang's profile →
Citations per field
00.5×
Jinfeng Tang · 1×
Citations per year

Countries citing papers authored by Peihong Wu

Since Specialization
Citations

This map shows the geographic impact of Peihong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peihong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peihong Wu more than expected).

Fields of papers citing papers by Peihong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peihong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peihong Wu. The network helps show where Peihong Wu may publish in the future.

Co-authorship network of co-authors of Peihong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Peihong Wu. A scholar is included among the top collaborators of Peihong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peihong Wu. Peihong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
#WorkIndexed citations
1 0
2 28
3 41
4 19
5 83
6 2
7
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberinebreakdown →
462

About Peihong Wu

Peihong Wu is a scholar working on Endocrinology, Diabetes and Metabolism, Hepatology and Reproductive Medicine, having authored 7 papers that have together received 635 indexed citations. Recurring topics across this work include Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers), Metabolism, Diabetes, and Cancer (2 papers) and Diabetes Management and Research (2 papers). The work is most often cited by research in Pharmacology (346 citations), Endocrinology, Diabetes and Metabolism (245 citations) and Pharmacology (121 citations). Peihong Wu has collaborated with scholars based in China. Frequent co-authors include Jialin Yang, Na Zhu, Guang Ning, Li Huo, Dajin Zou, Wei Liu, Jie Hong, Miao Wang, Yifei Zhang and Tao Tao. Their work appears in journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and BMJ Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026